At the conclusion of the 2025 Intelligent Optimization & Biomedical Industrialization Cross-Disciplinary Forum held in Xinxiang, Henan Province, Prof. Xinyan JI, editorial board member of GPD and Chief Scientist of the Henan Provincial Nuclear Proteomics Research Team, delivered a pivotal address underscoring the journal’s strategic role in advancing interdisciplinary biomedical innovation.

The forum, attended by leading experts from artificial intelligence, pharmaceutical R&D, clinical medicine, and venture capital, centered on the transformative potential of intelligent optimization algorithms in accelerating biomedical discovery and commercialization. Prof. Ji’s presentation articulated GPD’s mission to bridge fundamental genomic research with clinical translation, emphasizing the journal’s commitment to fostering cross-sector collaboration in the era of AI-driven science.

"In an age where machine learning and big data redefine disease mechanisms, academic journals must evolve beyond dissemination to catalyze innovation," Prof. Ji stated. "GPD is engineered to connect AI optimization with molecular disease pathways—enabling researchers to decode complex protein interactions, identify novel drug targets, and accelerate therapeutic development."

Prof. Ji detailed GPD’s rigorous editorial framework, including its globally diverse editorial board, stringent peer-review protocols, and strategic partnerships with AI-assisted publishing platforms. He highlighted the journal’s recent inclusion in CAS (Chemical Abstracts Service) and ASCI (Asian Science Citation Index) as evidence of its rising scholarly impact. Looking ahead, he outlined GPD’s roadmap for integrating open science principles, FAIR data standards, and AI-enhanced peer review to further empower the global research ecosystem.

The session sparked robust dialogue, with attendees—including industry leaders from Bayer, Novartis, and Huazhong University of Science and Technology—expressing strong alignment with GPD’s vision. Several proposed collaborative initiatives, including joint special issues on AI-Driven Drug Discovery and Protein-Protein Interaction Networks, were formally endorsed.

This forum marks a significant milestone in GPD’s mission to position itself as the nexus for genomics, proteomics, and intelligent optimization. By engaging with high-impact industry forums, the journal amplifies its visibility among translational researchers and accelerates the adoption of its platform for cutting-edge interdisciplinary work.